Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Feasibility of Patient-Reported Outcomes Measurement Information System (PROMIS®) computerized adaptive tests in systemic lupus erythematosus outpatients.

Kasturi S, Burket JC, Berman JR, Kirou KA, Levine AB, Sammaritano LR, Mandl LA.

Lupus. 2018 Jan 1:961203318778372. doi: 10.1177/0961203318778372. [Epub ahead of print]

PMID:
29793381
2.

Feasibility, Validity, and Reliability of the 10-item Patient Reported Outcomes Measurement Information System Global Health Short Form in Outpatients with Systemic Lupus Erythematosus.

Kasturi S, Szymonifka J, Burket JC, Berman JR, Kirou KA, Levine AB, Sammaritano LR, Mandl LA.

J Rheumatol. 2018 Mar;45(3):397-404. doi: 10.3899/jrheum.170590. Epub 2018 Feb 1.

PMID:
29419473
3.

Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8.

Ah Kioon MD, Tripodo C, Fernandez D, Kirou KA, Spiera RF, Crow MK, Gordon JK, Barrat FJ.

Sci Transl Med. 2018 Jan 10;10(423). pii: eaam8458. doi: 10.1126/scitranslmed.aam8458.

PMID:
29321259
4.

Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes.

Mavragani CP, Nezos A, Sagalovskiy I, Seshan S, Kirou KA, Crow MK.

J Autoimmun. 2018 Mar;88:75-82. doi: 10.1016/j.jaut.2017.10.004. Epub 2017 Oct 23.

PMID:
29074164
5.

Validity and Reliability of Patient Reported Outcomes Measurement Information System Computerized Adaptive Tests in Systemic Lupus Erythematosus.

Kasturi S, Szymonifka J, Burket JC, Berman JR, Kirou KA, Levine AB, Sammaritano LR, Mandl LA.

J Rheumatol. 2017 Jul;44(7):1024-1031. doi: 10.3899/jrheum.161202. Epub 2017 Apr 15.

PMID:
28412708
6.

Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE.

Rozo C, Chinenov Y, Maharaj RK, Gupta S, Leuenberger L, Kirou KA, Bykerk VP, Goodman SM, Salmon JE, Pernis AB.

Ann Rheum Dis. 2017 Apr;76(4):740-747. doi: 10.1136/annrheumdis-2016-209850. Epub 2016 Nov 9.

7.

Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease.

Mavragani CP, Sagalovskiy I, Guo Q, Nezos A, Kapsogeorgou EK, Lu P, Liang Zhou J, Kirou KA, Seshan SV, Moutsopoulos HM, Crow MK.

Arthritis Rheumatol. 2016 Nov;68(11):2686-2696. doi: 10.1002/art.39795.

8.

Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus.

Olferiev M, Jacek E, Kirou KA, Crow MK.

Clin Immunol. 2016 Nov;172:34-43. doi: 10.1016/j.clim.2016.08.018. Epub 2016 Aug 26.

PMID:
27576056
9.

What Causes Lupus Flares?

Fernandez D, Kirou KA.

Curr Rheumatol Rep. 2016 Mar;18(3):14. doi: 10.1007/s11926-016-0562-3. Review.

PMID:
26951252
10.

Minimal Change Disease as a Secondary and Reversible Event of a Renal Transplant Case with Systemic Lupus Erythematosus.

Gkrouzman E, Kirou KA, Seshan SV, Chevalier JM.

Case Rep Nephrol. 2015;2015:987212. doi: 10.1155/2015/987212. Epub 2015 Aug 13.

11.

Identification of Candidate Predictors of Lupus Flare.

Crow MK, Olferiev M, Kirou KA.

Trans Am Clin Climatol Assoc. 2015;126:184-96. Review.

12.

Targeting of type I interferon in systemic autoimmune diseases.

Crow MK, Olferiev M, Kirou KA.

Transl Res. 2015 Feb;165(2):296-305. doi: 10.1016/j.trsl.2014.10.005. Epub 2014 Oct 16. Review.

13.

Measuring interferon alpha and other cytokines in SLE.

Olferiev M, Lliguicota M, Kirou KA, Crow MK.

Methods Mol Biol. 2014;1134:131-50. doi: 10.1007/978-1-4939-0326-9_10.

PMID:
24497359
14.

A surge in anti-dsDNA titer predicts a severe lupus flare within six months.

Pan N, Amigues I, Lyman S, Duculan R, Aziz F, Crow MK, Kirou KA.

Lupus. 2014 Mar;23(3):293-8. doi: 10.1177/0961203313515763. Epub 2013 Dec 6.

PMID:
24316605
15.

Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations.

Mavragani CP, Niewold TB, Chatzigeorgiou A, Danielides S, Thomas D, Kirou KA, Kamper E, Kaltsas G, Crow MK.

Front Immunol. 2013 Aug 19;4:238. doi: 10.3389/fimmu.2013.00238. eCollection 2013.

16.

Anti-interferon alpha treatment in SLE.

Kirou KA, Gkrouzman E.

Clin Immunol. 2013 Sep;148(3):303-12. doi: 10.1016/j.clim.2013.02.013. Epub 2013 Mar 1. Review.

PMID:
23566912
17.

Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus.

Isgro J, Gupta S, Jacek E, Pavri T, Duculan R, Kim M, Kirou KA, Salmon JE, Pernis AB.

Arthritis Rheum. 2013 Jun;65(6):1592-602. doi: 10.1002/art.37934.

18.

Two systemic lupus erythematosus patients with severe pleurisy: similar presentations, different causes.

Gulati CM, Satlin MJ, Magro CM, Kirou KA.

Arthritis Care Res (Hoboken). 2013 Jun;65(6):1005-13. doi: 10.1002/acr.21988. No abstract available.

19.

Belimumab in systemic lupus erythematosus: an update for clinicians.

Kim SS, Kirou KA, Erkan D.

Ther Adv Chronic Dis. 2012 Jan;3(1):11-23. doi: 10.1177/2040622311424806.

20.

Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.

Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA, Chitkara P, Putterman C, Gross RL, Somers EC, Kirou KA, Ramsey-Goldman R, Hsieh C, Buyon JP, Dervieux T, Weinstein A.

Arthritis Rheum. 2012 Dec;64(12):4040-7. doi: 10.1002/art.34669.

21.

Antiinflammatory strategies, not just B cell depletion, are required for optimal therapy for severe proliferative lupus nephritis: comment on the article by Rovin et al.

Kirou KA, Gkrouzman E, Chevalier JM, Seshan SV.

Arthritis Rheum. 2012 Oct;64(10):3486; author reply 3486. doi: 10.1002/art.34617. No abstract available.

22.

Type I interferons as biomarkers in autoimmune diseases.

Kalliolias GD, Kirou KA.

Biomark Med. 2012 Apr;6(2):137-40. doi: 10.2217/BMM.12.8. No abstract available.

23.

Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps.

Dwivedi N, Upadhyay J, Neeli I, Khan S, Pattanaik D, Myers L, Kirou KA, Hellmich B, Knuckley B, Thompson PR, Crow MK, Mikuls TR, Csernok E, Radic M.

Arthritis Rheum. 2012 Apr;64(4):982-92. doi: 10.1002/art.33432. Epub 2011 Oct 27.

24.

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.

Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B; Lupus Interferon Skin Activity (LISA) Study Investigators.

Ann Rheum Dis. 2011 Nov;70(11):1905-13. doi: 10.1136/ard.2010.144485. Epub 2011 Jul 27.

PMID:
21798883
25.

Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-α and serologic autoimmunity in lupus patients.

Robinson T, Kariuki SN, Franek BS, Kumabe M, Kumar AA, Badaracco M, Mikolaitis RA, Guerrero G, Utset TO, Drevlow BE, Zaacks LS, Grober JS, Cohen LM, Kirou KA, Crow MK, Jolly M, Niewold TB.

J Immunol. 2011 Aug 1;187(3):1298-303. doi: 10.4049/jimmunol.1100857. Epub 2011 Jun 24.

26.

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK.

Ann Rheum Dis. 2011 Jun;70(6):1003-9. doi: 10.1136/ard.2010.143974. Epub 2011 Mar 11.

27.

A 26-year-old white man with a systemic lupus erythematosus flare and acute multiorgan ischemia: Vasculitis or thrombosis?

Cherian J, Duculan R, Amigues I, Crow MK, Kirou KA.

Arthritis Care Res (Hoboken). 2011 May;63(5):766-74. doi: 10.1002/acr.20439. No abstract available.

28.

A new tool for detection of type I interferon activation in systemic lupus erythematosus.

Kirou KA, Kalliolias GD.

Arthritis Res Ther. 2010;12(4):138. doi: 10.1186/ar3114. Epub 2010 Aug 26.

29.

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.

Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, van Baarsen LG, Bos C, Kirou KA, Gerlag DM, Crow MK, Bijlsma JW, Verweij CL, Tak PP.

Arthritis Rheum. 2010 Dec;62(12):3607-14. doi: 10.1002/art.27702.

30.

Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus.

Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB.

Genes Immun. 2009 Jul;10(5):487-94. doi: 10.1038/gene.2009.15. Epub 2009 Apr 2.

31.

Interferon-induced versus chemokine transcripts as lupus biomarkers.

Crow MK, Kirou KA.

Arthritis Res Ther. 2008;10(6):126. doi: 10.1186/ar2559. Epub 2008 Dec 18.

32.

Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo.

Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB.

J Immunol. 2009 Jan 1;182(1):34-8.

33.

Activation of type I interferon in systemic lupus erythematosus.

Kirou KA, Mavragani CP, Crow MK.

Expert Rev Clin Immunol. 2007 Jul;3(4):579-88. doi: 10.1586/1744666X.3.4.579.

PMID:
20477162
34.

Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases.

Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG.

J Autoimmun. 2006 May;26(3):165-71. Epub 2006 Apr 18.

PMID:
16621447
35.

Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system.

Kirou KA, Salmon JE, Crow MK.

Rheum Dis Clin North Am. 2006 Feb;32(1):103-19, ix. Review.

PMID:
16504824
36.
37.

Cytokine-mediated regulation of activating and inhibitory Fc gamma receptors in human monocytes.

Liu Y, Masuda E, Blank MC, Kirou KA, Gao X, Park MS, Pricop L.

J Leukoc Biol. 2005 May;77(5):767-76. Epub 2005 Feb 9.

PMID:
15703199
38.

Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus.

Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK.

Arthritis Rheum. 2004 Dec;50(12):3958-67.

39.

Interferon-alpha in systemic lupus erythematosus.

Crow MK, Kirou KA.

Curr Opin Rheumatol. 2004 Sep;16(5):541-7. Review.

PMID:
15314491
40.

Measurement of cytokines in autoimmune disease.

Kirou KA, Lee C, Crow MK.

Methods Mol Med. 2004;102:129-54.

PMID:
15286384
41.

Microarray analysis of interferon-regulated genes in SLE.

Crow MK, Kirou KA, Wohlgemuth J.

Autoimmunity. 2003 Dec;36(8):481-90. Review.

PMID:
14984025
42.
43.

Regulation of CD40 ligand expression in systemic lupus erythematosus.

Crow MK, Kirou KA.

Curr Opin Rheumatol. 2001 Sep;13(5):361-9. Review.

PMID:
11604589
44.

Sarcoidosis presenting with large vessel vasculitis and osteosclerosis-related bone and joint pain.

Kirou KA, Bateman HE, Bansal M, Schneider R, Fantini GA, Paget SA.

Clin Exp Rheumatol. 2000 May-Jun;18(3):401-3.

PMID:
10895383
45.

Induction of Fas ligand-mediated apoptosis by interferon-alpha.

Kirou KA, Vakkalanka RK, Butler MJ, Crow MK.

Clin Immunol. 2000 Jun;95(3):218-26.

PMID:
10866129
46.

Remission of juvenile rheumatoid arthritis after infection with parvovirus B19.

Bateman HE, Kirou KA, Paget SA, Crow MK, Yee AM.

J Rheumatol. 1999 Nov;26(11):2482-4.

PMID:
10555914
47.

Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera.

Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK.

Arthritis Rheum. 1999 May;42(5):871-81.

48.

New pieces to the SLE cytokine puzzle.

Kirou KA, Crow MK.

Clin Immunol. 1999 Apr;91(1):1-5. Review. No abstract available.

PMID:
10219248

Supplemental Content

Loading ...
Support Center